Home > Browse Issues > Vol.44 No.7

The Research Status and Optimizing Strategy of Mesenchymal Stem Cells Therapy for Myocardial Infarction

YANG Jiawei^1,2,3, WANG Xianyun^2,3,4, WANG Le^1,2,3, YIN Yajuan^1,2,3, LIU Dongyue^1,2,3, DING Lini^1,2,3, ZHENG Mingqi^1,2,3, LIU Gang^1,2,3*

(¹Department of Cardiology, the First Hospital of Hebei Medical University, Shijiazhuang 050030, China; ²Cell Therapy Laboratory, the First Hospital of Hebei Medical University, Shijiazhuang 050030, China; ³Key Laboratory, Hebei Provincial Cardiology and Metabolism, Shijiazhuang 050030, China; ⁴International Joint Research Center, Hebei Provincial Structural heart disease, Shijiazhuang 050030, China)

Abstract:

Heart failure after MI (myocardial infarction) remains one of the leading causes of death and disability worldwide. Although drugs and interventional therapy can restore blood supply to the heart timely, the regenerative capacity of myocardial cells is too low to improve damaged heart function, which can seriously lead to heart failure and even death. At present, both basic and clinical studies have shown that MSCs (mesenchymal stem cells) can effectively improve the repair of cardiac function after MI, and optimized and improved MSCs have become increasingly important in the treatment of MI and other diseases. Therefore, this article will respectively review the progress of the primary mechanism of MSCs, the recent status of MSCs and transplantation pathway and the optimizing strategy in the treatment of myocardial infarction.

CSTR: 32200.14.cjcb.2022.07.0022